Exact Sciences - EXAS Stock Forecast, Price & News

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

Exact Sciences Stock Performance

EXAS opened at $47.05 on Monday. Exact Sciences has a fifty-two week low of $35.34 and a fifty-two week high of $108.99. The company has a debt-to-equity ratio of 0.70, a quick ratio of 2.23 and a current ratio of 2.48. The company has a fifty day moving average of $44.58 and a 200 day moving average of $58.76. The stock has a market capitalization of $8.33 billion, a price-to-earnings ratio of -11.12 and a beta of 1.32.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the stock. Cowen dropped their target price on shares of Exact Sciences from $83.00 to $67.00 and set an "outperform" rating on the stock in a research note on Wednesday, August 3rd. Craig Hallum dropped their target price on shares of Exact Sciences from $81.00 to $60.00 and set a "buy" rating on the stock in a research note on Wednesday, August 3rd. Robert W. Baird dropped their target price on shares of Exact Sciences from $90.00 to $75.00 and set an "outperform" rating on the stock in a research note on Wednesday, August 3rd. Piper Sandler started coverage on shares of Exact Sciences in a research report on Thursday, June 2nd. They set a "neutral" rating and a $50.00 price objective on the stock. Finally, StockNews.com upgraded shares of Exact Sciences from a "sell" rating to a "hold" rating in a research report on Tuesday, July 26th. Four equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat.com, Exact Sciences has a consensus rating of "Moderate Buy" and a consensus price target of $73.09.

Insider Buying and Selling at Exact Sciences

In other news, Director Katherine S. Zanotti sold 4,608 shares of the firm's stock in a transaction dated Tuesday, July 26th. The shares were sold at an average price of $45.14, for a total value of $208,005.12. Following the completion of the sale, the director now owns 60,318 shares in the company, valued at approximately $2,722,754.52. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other news, Director Katherine S. Zanotti sold 4,608 shares of the firm's stock in a transaction dated Tuesday, July 26th. The shares were sold at an average price of $45.14, for a total value of $208,005.12. Following the completion of the sale, the director now owns 60,318 shares in the company, valued at approximately $2,722,754.52. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Katherine S. Zanotti sold 1,086 shares of the firm's stock in a transaction dated Thursday, June 30th. The stock was sold at an average price of $40.13, for a total transaction of $43,581.18. Following the completion of the sale, the director now owns 60,318 shares of the company's stock, valued at approximately $2,420,561.34. The disclosure for this sale can be found here. Insiders sold 5,701 shares of company stock worth $251,872 over the last 90 days. 1.30% of the stock is owned by insiders.